No abstract available.
Enzyme-Linked Immunosorbent Assay*

No abstract available.
Enzyme-Linked Immunosorbent Assay*

No abstract available.
Enzyme-Linked Immunosorbent Assay*

No abstract available.
Enzyme-Linked Immunosorbent Assay* ; Korea*

No abstract available.
Autopsy* ; Enzyme-Linked Immunosorbent Assay*

OBJECTIVE: To investigate how many leiomyoma patients are exposed to bisphenol-A (BPA) and whether the serum concentration of BPA is related to leiomyoma growth. METHODS: Total 131 patients were recruited for measuring BPA. Initially, leiomyoma patients were divided into three groups, mild (n=38), moderate (n=33), and severe (n=30) according to the size of the leiomyomas. The control (n=30) group was defined as having no leiomyomas. The identification and diameter measurements of leiomyomas was performed by transvaginal ultrasonography. Serum BPA concentrations were measured by enzyme linked immunosorbent assay. RESULTS: BPA was detected in 83.9% out of 131 samples totally, and 83.1% out of 101 leiomyoma patients. In detail, the detection rates of serum BPA were 86.7% in control group, 71.1% in mild group, 84.9% in moderate group, and 96.7% in severe group. The mean BPA concentrations in the control group was 0.557+/-0.086 ng/mL and those in the leiomyoma groups were 0.273+/-0.052 ng/mL (mild), 0.336+/-0.063 ng/mL (moderate), and 0.636+/-0.075 ng/mL (severe) (P=0.0003). Values are mean+/-standard error. Conclusions: The detection rate of serum BPA in control and leiomyoma groups were 86.7% and 83.1% respectively. However, there was no statistical significance of serum BPA concentrations between control and leiomyoma groups. To verify the effect of BPA on the leiomyoma growth, close and sequential monitoring for the person who have exposure risk is recommended.
Enzyme-Linked Immunosorbent Assay ; Humans ; Leiomyoma

No Abstract Available.
Cytomegalovirus* ; Enzyme-Linked Immunosorbent Assay* ; Humans*

No Abstract Available.
Diagnosis* ; Enzyme-Linked Immunosorbent Assay* ; Flagellin* ; Leptospirosis*

BACKGROUND: The aim of our study was to optimize and establish erythropoietin (EPO) enzyme linked immunosorbent assay (ELISA) system. METHODS: We prepared several monoclonal and polyclonal antibodies specific to human-EPO. The best combinations of antibodies for coating and detecting antibodies were selected for the establishment of ELISA. We tested several methods such as a competitive EIA and a sandwich ELISA. RESULTS: The best sandwich ELISA was optimized compared to competitive EIA when purified polyclonal antibody (PoAb) was used as a coating antibody and biotinylated PoAb as a detecting antibody. This sandwich ELISA easily detected EPO when PoAb pairs were used compared to the ELISA using monoclonal antibody and PoAb. There were no significant differences between the effects of various blocking solutions on the performance of sandwich ELISA using biotinylated antibody. The ELISA system using PBST containing 3% BSA as a blocking solution can sensitively detect EPO (10 mU/mL) in a broad range of EPO concentrations (10-2,000 mU/mL) and there were cross-reactions with other cytokines). CONCLUSIONS: EPO can be easily determined by using biotinylated PoAb as a detecting antibody and another PoAb as a coating antibody.
Antibodies ; Enzyme-Linked Immunosorbent Assay* ; Erythropoietin*

In Trang An polyclinics in Ha Noi, with ELISA technique, 35 healthy people (27 female aged 20-38, 8 male aged 25-37) undergone an examination of serum CA153-3 and 31 other healthy people (17 female aged 21-38, 14 male aged 22-41) an examination of resum CA125. The technique is complicated needing precaution and accuracy; for each examination, it is recommended a standard graphic with a standard sample determined antigen concentration. CA15-3 normal concentration is 2.37-18.17 U/ml, and CA125 is 7.17-38.37 U/ml
Enzyme-Linked Immunosorbent Assay ; methods ; serum